[Inhibition of lactation with lisuride. CLinical evaluation].
Lactation in humans requires the collaboration of neural and endocrine systems. During pregnancy and after parturition prolactin and also sex steroids, corticoids, growth hormone and human placental lactogen are necessary for lactogenesis. In an open, simple and prospective study, 50 women with normal delivery or cesarean section, between 34 and 41 weeks of gestation, were treated with lisuride, 0.2 mg t.i.d. for 14 days in order to inhibit lactation. The arrest of lactation was mandatory for medical reasons and the results were evaluated by changes in breast related with shape, volume, symmetry, coloring, temperature, turgescence, venous appearance, nipple condition, colostrum and lymph nodes increase. Lactation that was already present in 87% of patients in the first exploration 24 hours after delivery was satisfactorily suppressed and also breast pain, engorgement and discomfort caused by milk leakage. None had rebound lactation. 5 patients had light nausea. The dopamine agonist lisuride can be used for primary arrest of lactation with clinical effectiveness and without potential dangerous side effects of hormonal compounds.
Sereno Coló
J A
JA
Hospital General Dr. Miguel Silva, SSA. Morelia, Mich. México.
Navarrete Horta
M T
MT
D000293:Adolescent; D000328:Adult; D001458:Bandages; D001940:Breast / Q000187:drug effects; D003131:Combined Modality Therapy; D003864:Depression, Chemical; D004326:Drinking; D005260:Female; D006801:Humans; D007774:Lactation / Q000187:drug effects*; D008090:Lisuride / Q000009:adverse effects / Q000494:pharmacology*; D009325:Nausea / Q000139:chemically induced; D011247:Pregnancy; D011388:Prolactin / Q000378:metabolism; D011446:Prospective Studies; D016896:Treatment Outcome
D011388:Prolactin; D008090:Lisuride
Inhibición de la lactancia con lisurida. Evaluación clínica.